Total Pageviews

8/04/2013

Операция в Аль Кабуне. Часть 8.2. Автовокзал. Продолжение атаки на левом...

1 comment:

  1. BRAF inhibitors and MEK inhibitor combination therapy BRAF V600 mutations in melanoma patients

    Melanoma patients with brain metastases poor prognosis with a median survival of less than four months, there was no significant effect systemic therapy, in addition to radiotherapy currently has almost no other treatment options. However, BRAF inhibitors dabrafenib appears, for BRAFV600E / K mutations in melanoma patients with brain metastases hope. Study confirmed, BRAF inhibitor dabrafenib and MEK inhibitor trametinib whole joint is safe and effective amount of the combination therapy group, the incidence of proliferative skin lesions and the combined treatment group decreased significantly improved PFS.

    This is the world's first targeted therapy in combination with reduced incidence of adverse reactions after a significant improvement in PFS and clinical trials, the delay of a small molecule kinase inhibitor drug, individualized targeted therapy to guide further development strategy is of great significance.

    Medchemexpress Can provide the above product,its website:www.medchemexpress.com



    Lurasidone Hydrochloride
    Adoprazine
    Rotigotine
    Rotigotine hydrochloride
    HOKU-81
    Olmesartan
    Olmesartan medoxomil
    BML-190
    AM630
    Adoprazine

    ReplyDelete